The Association between Blood-Based Global DNA Methylation and Venous Thromboembolism

Xiao Wang; Ashfaque A. Memon; Karolina Palmér; Peter J. Svensson; Jan Sundquist; Kristina Sundquist

doi:10.1055/s-0040-1722271

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2021; 47(06): 662-668
DOI: 10.1055/s-0040-1722271

Review Article

The Association between Blood-Based Global DNA Methylation and Venous Thromboembolism

Xiao Wang

¹Center for Primary Health Care Research, Lund University, Malmö, Sweden

,

Ashfaque A. Memon

¹Center for Primary Health Care Research, Lund University, Malmö, Sweden

,

Karolina Palmér

¹Center for Primary Health Care Research, Lund University, Malmö, Sweden

,

Peter J. Svensson

²Department of Coagulation Disorders, Lund University Hospital, Malmö, Sweden

,

Jan Sundquist

¹Center for Primary Health Care Research, Lund University, Malmö, Sweden

³Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York

⁴Department of Functional Pathology, Center for Community-based Healthcare Research and Education (CoHRE), School of Medicine, Shimane University, Izumo, Japan

,

Kristina Sundquist

¹Center for Primary Health Care Research, Lund University, Malmö, Sweden

³Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York

⁴Department of Functional Pathology, Center for Community-based Healthcare Research and Education (CoHRE), School of Medicine, Shimane University, Izumo, Japan

› Institutsangaben

Abstract

Alterations in DNA methylation patterns have been associated with many diseases. However, the role of DNA methylation in venous thromboembolism (VTE) is not well established. The aim of this study was to investigate a possible association between global DNA methylation and VTE. The study participants consisted of 168 individuals including 74 patients with primary VTE from the Malmö Thrombophilia Study (MATS) and 94 healthy controls. Among 74 primary VTE patients, 37 suffered VTE recurrence during the follow-up period; 37 nonrecurrent VTE patients were included for comparison. Blood-based global DNA methylation was assessed by an enzyme-linked immunosorbent assay. Global DNA methylation was significantly higher in primary VTE patients compared with the healthy controls (median: 0.17 vs. 0.08%; p < 0.001). After stratification of data from primary VTE patients according to sex, the association between higher global DNA methylation and shorter recurrence-free survival time was of borderline statistical significance in males (β = –0.2; p = 0.052) but not in females (β = 0.02; p = 0.90). Our results show that global DNA methylation is associated with primary VTE and that higher levels of global DNA methylation may be associated with early VTE recurrence in males but not in females. Further investigation on the role of DNA methylation as a diagnostic or preventive biomarker in VTE is warranted.

Keywords

venous thromboembolism - DNA methylation - recurrent venous thromboembolism

Volltext

Referenzen

References
1 Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12 (08) 464-474
2 Heit JA, Phelps MA, Ward SA, Slusser JP, Petterson TM, De Andrade M. Familial segregation of venous thromboembolism. J Thromb Haemost 2004; 2 (05) 731-736
3 Heit JA, Armasu SM, Asmann YW. et al. A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q. J Thromb Haemost 2012; 10 (08) 1521-1531
4 Desch KC. Dissecting the genetic determinants of hemostasis and thrombosis. Curr Opin Hematol 2015; 22 (05) 428-436
5 Benincasa G, Costa D, Infante T, Lucchese R, Donatelli F, Napoli C. Interplay between genetics and epigenetics in modulating the risk of venous thromboembolism: a new challenge for personalized therapy. Thromb Res 2019; 177: 145-153
6 Morange PE, Suchon P, Trégouët DA. Genetics of venous thrombosis: update in 2015. Thromb Haemost 2015; 114 (05) 910-919
7 Reitsma PH, Versteeg HH, Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 2012; 32 (03) 563-568
8 Riva N, Donadini MP, Ageno W. Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation. Thromb Haemost 2015; 113 (06) 1176-1183
9 Prandoni P, Noventa F, Ghirarduzzi A. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92 (02) 199-205
10 Bird A. Perceptions of epigenetics. Nature 2007; 447 (7143): 396-398
11 Feinberg AP. The key role of epigenetics in human disease prevention and mitigation. N Engl J Med 2018; 378 (14) 1323-1334
12 Maddatu J, Anderson-Baucum E, Evans-Molina C. Smoking and the risk of type 2 diabetes. Transl Res 2017; 184: 101-107
13 Wang X, Sundquist K, Elf JL. et al. Diagnostic potential of plasma microRNA signatures in patients with deep-vein thrombosis. Thromb Haemost 2016; 116 (02) 328-336
14 Wang X, Sundquist K, Svensson PJ. et al. Association of recurrent venous thromboembolism and circulating microRNAs. Clin Epigenetics 2019; 11 (01) 28
15 Thirlwell C, Eymard M, Feber A. et al. Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip. Methods 2010; 52 (03) 248-254
16 Salameh Y, Bejaoui Y, El Hajj N. DNA methylation biomarkers in aging and age-related diseases. Front Genet 2020; 11: 171
17 Mikeska T, Craig JM. DNA methylation biomarkers: cancer and beyond. Genes (Basel) 2014; 5 (03) 821-864
18 Willmer T, Johnson R, Louw J, Pheiffer C. Blood-based DNA methylation biomarkers for type 2 diabetes: potential for clinical applications. Front Endocrinol (Lausanne) 2018; 9: 744
19 Payne SR. From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood. Epigenomics 2010; 2 (04) 575-585
20 Kim M, Long TI, Arakawa K, Wang R, Yu MC, Laird PW. DNA methylation as a biomarker for cardiovascular disease risk. PLoS One 2010; 5 (03) e9692
21 Udali S, Guarini P, Moruzzi S. et al. Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate. Hepatology 2015; 62 (02) 496-504
22 Isma N, Svensson PJ, Gottsäter A, Lindblad B. Prospective analysis of risk factors and distribution of venous thromboembolism in the population-based Malmö Thrombophilia Study (MATS). Thromb Res 2009; 124 (06) 663-666
23 Rocañín-Arjó A, Dennis J, Suchon P. et al. Thrombin generation potential and whole-blood DNA methylation. Thromb Res 2015; 135 (03) 561-564
24 Peng Y, Jahroudi N. The NFY transcription factor inhibits von Willebrand factor promoter activation in non-endothelial cells through recruitment of histone deacetylases. J Biol Chem 2003; 278 (10) 8385-8394
25 Friso S, Lotto V, Choi SW. et al. Promoter methylation in coagulation F7 gene influences plasma FVII concentrations and relates to coronary artery disease. J Med Genet 2012; 49 (03) 192-199
26 El-Maarri O, Becker T, Junen J. et al. Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males. Hum Genet 2007; 122 (05) 505-514
27 Nojima M, Iwasaki M, Kasuga Y. et al. Correlation between global methylation level of peripheral blood leukocytes and serum C reactive protein level modified by MTHFR polymorphism: a cross-sectional study. BMC Cancer 2018; 18 (01) 184